Covered recipient · General Payments record
IDELLA N SIMMONS
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,903.04
- Reported across 203 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $529.06 | 36 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $197.21 | 9 |
| ABBVIE INC. | $165.58 | 13 |
| Lilly USA, LLC | $133.10 | 12 |
| Acerta Pharma LLC | $18.30 | 1 |
| PFIZER INC. | $14.87 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (36)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $7.59 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105165 | CMS |
| ABBVIE INC. | $20.95 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105167 | CMS |
| ABBVIE INC. | $14.69 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105169 | CMS |
| ABBVIE INC. | $9.61 | 03/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105171 | CMS |
| ABBVIE INC. | $7.96 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105173 | CMS |
| ABBVIE INC. | $10.37 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105175 | CMS |
| ABBVIE INC. | $10.14 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105177 | CMS |
| ABBVIE INC. | $11.62 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105179 | CMS |
| ABBVIE INC. | $17.78 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105181 | CMS |
| ABBVIE INC. | $8.99 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105183 | CMS |
| ABBVIE INC. | $5.41 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105185 | CMS |
| ABBVIE INC. | $11.64 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105187 | CMS |
| ABBVIE INC. | $28.83 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106105189 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.30 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105481011 | CMS |
| Lilly USA, LLC | $7.32 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135032108 | CMS |
| Lilly USA, LLC | $9.78 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134984684 | CMS |
| Lilly USA, LLC | $10.49 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134984686 | CMS |
| Lilly USA, LLC | $11.85 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025296 | CMS |
| Lilly USA, LLC | $15.02 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135008293 | CMS |
| Lilly USA, LLC | $11.02 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025294 | CMS |
| Lilly USA, LLC | $9.80 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135032110 | CMS |
| Lilly USA, LLC | $13.23 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135008291 | CMS |
| Lilly USA, LLC | $1.45 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135005789 | CMS |
| Lilly USA, LLC | $9.75 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025122 | CMS |
| Lilly USA, LLC | $13.59 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135025124 | CMS |
| Lilly USA, LLC | $19.80 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135007603 | CMS |
| Novo Nordisk Inc | $8.92 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096849932 | CMS |
| Novo Nordisk Inc | $1.15 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097834676 | CMS |
| Novo Nordisk Inc | $9.64 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097400195 | CMS |
| Novo Nordisk Inc | $12.18 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097429449 | CMS |
| Novo Nordisk Inc | $10.00 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096591520 | CMS |
| Novo Nordisk Inc | $121.18 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097669509 | CMS |
| Novo Nordisk Inc | $10.34 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097661824 | CMS |
| Novo Nordisk Inc | $12.43 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097612871 | CMS |
| Novo Nordisk Inc | $11.37 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096575673 | CMS |
| PFIZER INC. | $14.87 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131653622 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.